샘플 요청 목록

 카트 문의
시장보고서
상품코드
1785919

세계의 카페시타빈(Capecitabine) 시장

Capecitabine
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 220 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 카페시타빈(Capecitabine) 시장은 2030년까지 5억 2,870만 달러에 달할 전망

2024년에 4억 2,740만 달러로 추정되는 세계의 카페시타빈 시장은 2024-2030년에 CAGR 3.6%로 성장하며, 2030년에는 5억 2,870만 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 화학 기반 API는 CAGR 4.3%를 기록하며, 분석 기간 종료시에는 2억 3,350만 달러에 달할 것으로 예측됩니다. 생물학적 API 부문의 성장률은 분석 기간에 CAGR 3.3%로 추정됩니다.

미국 시장은 1억 1,640만 달러로 추정, 중국은 CAGR 6.8%로 성장 예측

미국의 카페시타빈 시장은 2024년에 1억 1,640만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 1억 660만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 6.8%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.4%와 2.8%로 예측됩니다. 유럽에서는 독일이 CAGR 2.1%로 성장할 것으로 예측됩니다.

세계의 카페시타빈 시장 : 주요 동향과 촉진요인 정리

카페시타빈 시장의 성장을 가속하는 요인은 무엇인가?

카페시타빈 세계 시장은 암 발병률 증가와 효과적인 화학요법 치료에 대한 수요 증가로 인해 꾸준히 성장하고 있습니다. 경구용 화학요법제인 카페시타빈은 대장암, 유방암, 위암 치료에 널리 사용되고 있으며, 암 관리 프로토콜의 중요한 컴포넌트가 되고 있습니다. 생활습관의 변화, 인구 고령화, 유전적 소인 등으로 인해 암 환자는 증가하고 있으며, 효과적이고 내약성이 좋은 치료 옵션에 대한 요구는 계속 증가하고 있습니다. 정맥주사보다 경구용 화학요법이 환자들에게 더 편리하고 통원치료의 필요성을 줄일 수 있다는 점도 카페시타빈의 사용 확대에 영향을 미치고 있습니다.

종양학의 발전은 어떻게 카페시타빈의 보급을 촉진하고 있는가?

현재 진행 중인 연구와 임상시험에서 병용요법에서 카페시타빈의 효과를 검토하고 있습니다. 카페시타빈은 종종 다른 화학요법제나 표적치료제와 병용하여 치료 성적을 높이고 환자의 생존율을 향상시킵니다. 맞춤형 의료와 바이오마커 기반 암 치료의 혁신도 카페시타빈 시장에 영향을 미치고 있으며, 암 전문의들은 환자 개개인프로파일에 따라 치료 요법을 조정하고 있습니다. 또한 약물의 효능을 향상시키고 부작용을 최소화하기 위한 새로운 제형과 서방형 제제의 개발이 진행되고 있으며, 환자나 의료진에게 더욱 매력적인 선택지가 되고 있습니다.

신흥 헬스케어 시장에서 시장이 성장하는 이유는 무엇인가?

카페시타빈 시장은 특히 암 발병률이 증가하고 있는 아시아태평양, 라틴아메리카 등 신흥 헬스케어 시장에서 큰 성장세를 보이고 있습니다. 의료 서비스 접근성 향상, 암 치료에 대한 정부 구상 증가, 의약품 유통망 확대로 인해 더 많은 환자들이 카페시타빈을 쉽게 이용할 수 있게 되었습니다. 또한 카페시타빈의 제네릭 의약품이 저렴한 가격으로 출시되면서 중저소득 국가에서도 널리 사용되고 있습니다. 암 치료 시설의 확대와 조기 발견 및 치료에 대한 인식이 높아짐에 따라 카페시타빈 수요는 전 세계 시장에서 안정적으로 성장할 것으로 예측됩니다.

시장 확대를 촉진하는 요인은 무엇인가?

카페시타빈 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 전 세계 암 발병률 증가와 1차 치료 옵션으로 화학요법에 대한 관심이 높아지면서 시장 수요가 크게 증가하고 있습니다. 환자 중심의 치료 접근 방식으로의 전환으로 카페시타빈과 같은 경구용 화학요법제에 대한 선호도가 높아지고 있으며, 정맥요법에 비해 투여가 용이하고 삶의 질이 향상되고 있습니다. 또한 규제 당국의 승인과 현재 진행 중인 병용요법에 대한 연구로 인해 약물의 적용 범위가 확대되고 시장 가능성이 높아지고 있습니다. 또한 헬스케어 투자 증가와 비용 효율적인 제네릭 제제의 도입으로 카페시타빈은 다양한 계층에서 쉽게 사용할 수 있게 되어 시장의 지속적인 성장에 기여하고 있습니다.

부문

합성 유형(화학 기반 API, 생물학적 API, 고활성 API(HPAPI)), 적응증(유방암, 대장암, 위암, 췌장암, 기타 적응증)

조사 대상 기업의 예

  • Accord Healthcare Ltd.
  • Alkem Laboratories Ltd.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co. KGaA
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Drugs Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
  • Lupin Limited
  • MSN Laboratories Pvt. Ltd.
  • Mylan N.V.
  • Reliance Life Sciences Pvt. Ltd.
  • Shilpa Medicare Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.13

Global Capecitabine Market to Reach US$528.7 Million by 2030

The global market for Capecitabine estimated at US$427.4 Million in the year 2024, is expected to reach US$528.7 Million by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Chemical-based API, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$233.5 Million by the end of the analysis period. Growth in the Biological API segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$116.4 Million While China is Forecast to Grow at 6.8% CAGR

The Capecitabine market in the U.S. is estimated at US$116.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$106.6 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Capecitabine Market: Key Trends & Drivers Summarized

What Is Fueling the Growth of the Capecitabine Market?

The global capecitabine market is witnessing steady growth, driven by the increasing prevalence of cancer and the rising demand for effective chemotherapy treatments. Capecitabine, an oral chemotherapy drug, is widely used for the treatment of colorectal, breast, and gastric cancers, making it a crucial component of cancer management protocols. With cancer cases on the rise due to lifestyle changes, aging populations, and genetic predispositions, the need for effective and well-tolerated treatment options continues to grow. The preference for oral chemotherapy over intravenous administration has further contributed to the expanding use of capecitabine, as it offers greater convenience for patients and reduces the need for hospital visits.

How Are Advancements in Oncology Boosting Capecitabine Adoption?

The field of oncology is undergoing rapid advancements, with ongoing research and clinical trials exploring the efficacy of capecitabine in combination therapies. Capecitabine is often used in conjunction with other chemotherapy agents or targeted therapies to enhance treatment outcomes and improve patient survival rates. Innovations in personalized medicine and biomarker-driven cancer therapies have also influenced the capecitabine market, as oncologists increasingly tailor treatment regimens based on individual patient profiles. Additionally, new drug formulations and extended-release versions are being developed to improve the drug’s efficacy and minimize side effects, making it a more attractive option for both patients and healthcare providers.

Why Is the Market Growing in Emerging Healthcare Markets?

The capecitabine market is witnessing significant growth in emerging healthcare markets, particularly in Asia-Pacific and Latin America, where cancer incidence rates are rising. Improved access to healthcare, increasing government initiatives for cancer treatment, and the expansion of pharmaceutical distribution networks have made capecitabine more accessible to a larger patient population. Additionally, the growing affordability of generic versions of capecitabine has enabled wider adoption in low- and middle-income countries. With the expansion of cancer care facilities and increased awareness about early detection and treatment, the demand for capecitabine is expected to grow steadily across global markets.

What Factors Are Driving Market Expansion?

The growth in the capecitabine market is driven by several factors. The rising global burden of cancer and the increasing focus on chemotherapy as a primary treatment option have significantly boosted market demand. The shift towards patient-centric treatment approaches has led to a growing preference for oral chemotherapy drugs like capecitabine, which offer ease of administration and improved quality of life compared to intravenous therapies. Regulatory approvals and ongoing research into combination therapies have also expanded the drug’s applicability, enhancing its market potential. Additionally, increasing healthcare investments, coupled with the introduction of cost-effective generic formulations, are making capecitabine more accessible across diverse demographics, contributing to sustained market growth.

SCOPE OF STUDY:

The report analyzes the Capecitabine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Synthesis Type (Chemical-based API, Biological API, Highly Potent API (HPAPI)); Indication (Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Accord Healthcare Ltd.
  • Alkem Laboratories Ltd.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co. KGaA
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Drugs Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
  • Lupin Limited
  • MSN Laboratories Pvt. Ltd.
  • Mylan N.V.
  • Reliance Life Sciences Pvt. Ltd.
  • Shilpa Medicare Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Capecitabine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Colorectal and Breast Cancer Fueling Drug Demand
    • Growing Preference for Oral Chemotherapy Agents Enhancing Patient Compliance
    • Expansion of Targeted Therapy and Combination Regimens Increasing Usage
    • Increased Focus on Home-Based Cancer Treatment Modalities
    • Wider Drug Access Through National Cancer Care Programs in Emerging Economies
    • Ongoing Clinical Trials Supporting Expanded Indications for Capecitabine
    • Rising Geriatric Population Driving Long-Term Cancer Treatment Needs
    • Technological Advancements in Oncology Diagnostics Boosting Treatment Personalization
    • Improved Availability of Generics Increasing Affordability in Developing Markets
    • Healthcare Infrastructure Development Supporting Greater Drug Access
    • Supportive Reimbursement Frameworks in Developed Markets Driving Prescriptions
    • Growth in Awareness of Early Cancer Detection Elevating First-Line Therapy Demand
    • Increased Oncology R&D Pipelines Encouraging Adjunctive Use of Capecitabine
    • Collaborations Between Pharma Companies Enhancing Market Penetration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Capecitabine Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Capecitabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Capecitabine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Chemical-based API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Chemical-based API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Biological API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Biological API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Highly Potent API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Highly Potent API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gastric Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pancreatic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pancreatic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • CANADA
    • TABLE 24: Canada Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • JAPAN
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 28: Japan Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • CHINA
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 34: China Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • EUROPE
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Capecitabine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 37: Europe 6-Year Perspective for Capecitabine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • FRANCE
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 42: France Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: France 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 44: France Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • GERMANY
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 46: Germany Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Germany 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 54: UK Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: UK 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 56: UK Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • SPAIN
    • TABLE 58: Spain Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Spain 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 60: Spain Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Spain 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • RUSSIA
    • TABLE 62: Russia Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Russia 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 64: Russia Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Russia 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 66: Rest of Europe Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of Europe 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 68: Rest of Europe Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Europe 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 70: Asia-Pacific Recent Past, Current & Future Analysis for Capecitabine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 71: Asia-Pacific 6-Year Perspective for Capecitabine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 72: Asia-Pacific Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Asia-Pacific 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 74: Asia-Pacific Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Asia-Pacific 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • AUSTRALIA
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 76: Australia Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Australia 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 78: Australia Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Australia 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • INDIA
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 80: India Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: India 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 82: India Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: India 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 84: South Korea Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: South Korea 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 86: South Korea Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: South Korea 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 88: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Asia-Pacific 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 90: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Asia-Pacific 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • LATIN AMERICA
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 92: Latin America Recent Past, Current & Future Analysis for Capecitabine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Latin America 6-Year Perspective for Capecitabine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 94: Latin America Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Latin America 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 96: Latin America Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Latin America 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 98: Argentina Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Argentina 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 100: Argentina Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Argentina 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • BRAZIL
    • TABLE 102: Brazil Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Brazil 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 104: Brazil Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Brazil 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • MEXICO
    • TABLE 106: Mexico Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Mexico 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 108: Mexico Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Mexico 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 110: Rest of Latin America Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Latin America 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 112: Rest of Latin America Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Latin America 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • MIDDLE EAST
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 114: Middle East Recent Past, Current & Future Analysis for Capecitabine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 115: Middle East 6-Year Perspective for Capecitabine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 116: Middle East Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Middle East 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 118: Middle East Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Middle East 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • IRAN
    • TABLE 120: Iran Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Iran 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 122: Iran Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Iran 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • ISRAEL
    • TABLE 124: Israel Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Israel 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 126: Israel Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Israel 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 128: Saudi Arabia Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Saudi Arabia 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 130: Saudi Arabia Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Saudi Arabia 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 132: UAE Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: UAE 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 134: UAE Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UAE 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 136: Rest of Middle East Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of Middle East 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 138: Rest of Middle East Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of Middle East 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030
  • AFRICA
    • Capecitabine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 140: Africa Recent Past, Current & Future Analysis for Capecitabine by Synthesis Type - Chemical-based API, Biological API and Highly Potent API - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Africa 6-Year Perspective for Capecitabine by Synthesis Type - Percentage Breakdown of Value Sales for Chemical-based API, Biological API and Highly Potent API for the Years 2025 & 2030
    • TABLE 142: Africa Recent Past, Current & Future Analysis for Capecitabine by Indication - Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Africa 6-Year Perspective for Capecitabine by Indication - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer and Other Indications for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제